HighGravityDataCurrent guidance
13 items
Ionis Pharmaceuticals
Guidance from Ionis Pharmaceuticals’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Jul 29, 2026
Data checked
Jul 29, 2026
What changed in the Jul 29, 2026 release
Each item compared with the same item in the previous release (Apr 29, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| New | Cashflow breakeven goal | for FY2028 | — | “cashflow breakeven in 2028” | Filing ↗ |
| New | DAWNZERA full year 2026 product sales | for FY2026 | — | “$110-120 million” | Filing ↗ |
| New | Operating expense growth | for FY2026 | — | “low-teens percentage growth year-over-year” | Filing ↗ |
| New | TRYNGOLZA full year 2026 product sales | for FY2026 | — | “$100-110 million” | Filing ↗ |
Show 4 items not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | Annual olezarsen peak net sales | for FY2026 | “>$3 billion” | — | Filing ↗ |
| Not restated | Total Revenue | for FY2026 | “$875-900 million” | — | Filing ↗ |
| Not restated | Cash, cash equivalents and short-term investments | for FY2026 | “>$1.6 billion” | — | Filing ↗ |
| Not restated | Operating loss on a non-GAAP basis | for FY2026 | “$425-475 million” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Annual olezarsen peak net sales | “>$3 billion” | for FY2026 | GAAP-tied | Apr 29, 2026 | 1 | Filing ↗ |
| Total Revenue | “$875-900 million” | for FY2026 | GAAP-tied | Apr 29, 2026 | 1 | Filing ↗ |
| Cash, cash equivalents and short-term investments | “>$1.6 billion” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| DAWNZERA full year 2026 product sales | “$110-120 million” | for FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| DAWNZERA product sales, net | “$110-120 million” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Operating expense growth | “low-teens percentage growth year-over-year” | for FY2026 | GAAP-tied | Jul 29, 2026 | 1 | Filing ↗ |
| Operating loss on a non-GAAP basis | “$425-475 million” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| TRYNGOLZA full year 2026 product sales | “$100-110 million” | for FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| TRYNGOLZA product sales, net | “$100-110 million” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
Next year and medium term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Cash flow breakeven | “achieve cash flow breakeven in 2028” | for FY2028 | Company-defined | Oct 29, 2025 | 1 | Filing ↗ |
| Cash flow breakeven target | “achieve cash flow breakeven in 2028” | for FY2028 | Company-defined | Jan 12, 2026 | 1 | Filing ↗ |
| Cashflow breakeven goal | “cashflow breakeven in 2028” | for FY2028 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Goal of reaching cash-flow breakeven | “cash-flow breakeven in 2028” | for FY2028 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
How one item moved
Cash, cash equivalents and short-term investments, for FY2025 — every statement across the year, each linked to its filing.
How your Biopharma sector group guides
12 companies in Biopharma. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| BioMarin Pharmaceutical | Aug 6, 2026 | 19 changes |
| Halozyme Therapeutics | Aug 6, 2026 | 6 changes |
| Eli Lilly | Aug 5, 2026 | 5 changes |
| Amgen | Aug 4, 2026 | 5 changes |
| Gilead Sciences | Aug 4, 2026 | 15 changes |
| Moderna | Jul 31, 2026 | 8 changes |
| Neurocrine Biosciences | Jul 30, 2026 | 16 changes |
| Regeneron Pharmaceuticals | Jul 30, 2026 | 22 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2028 | FY2026 | FY2025 | FY2024 | No period |
|---|---|---|---|---|---|
| Annual olezarsen peak net sales | — | 1 statement | — | — | 1 statement |
| Revenue | — | — | 1 statement | — | — |
| Total Revenue | — | 1 statement | 2 statements | — | — |
| TRYNGOLZA (olezarsen) annual peak net sales for sHTG | — | — | 1 statement | — | — |
| Cash | — | — | — | 1 statement | — |
The full record for Ionis Pharmaceuticals and its Biopharma peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Jul 29, 2026 | FY2026 Q2 | 0001140361-26-029960 | 4 | Open filing ↗ |
| Apr 29, 2026 | FY2026 Q1 | 0001140361-26-017637 | 7 | Open filing ↗ |
| Jan 12, 2026 | FY2025 Q4 | 0001140361-26-000893 | 3 | Open filing ↗ |
| Oct 29, 2025 | FY2025 Q3 | 0001140361-25-039650 | 4 | Open filing ↗ |
| Jul 30, 2025 | FY2025 Q2 | 0001140361-25-027949 | 3 | Open filing ↗ |
| Apr 30, 2025 | FY2025 Q1 | 0001140361-25-016562 | 4 | Open filing ↗ |
| Feb 19, 2025 | FY2024 Q4 | 0001140361-25-005080 | 2 | Open filing ↗ |
| Nov 6, 2024 | FY2024 Q3 | 0001140361-24-045370 | 2 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error